Structure Therapeutics Inc.
NASDAQStructure Therapeutics heads into its August 13 earnings event with short sellers stepping back, options traders leaning decisively long, and analysts trimming targets on a stock that just posted its best week in months. The most striking feature of the current setup is how aggressively options positioning has tilted to the call side. The put/call ratio hit 0.17 on Thursday…
Snapshot as of 5 Sept 2026
Structure Therapeutics heads into its August 13 earnings event with short sellers stepping back, options traders leaning decisively long, and analysts trimming targets on a stock that just posted its best week in…
GPCR enters the week with a sharp split between the data and the price action. The most important development is the publication of Phase 2b results for aleniglipron in Nature Medicine on June 5. The data showed up to…
GPCR heads into its Q1 2026 earnings print with the options market sending its most bullish signal of the year — even as the stock has shed nearly a quarter of its value over the past month. The divergence is the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GPCR — free to start on ORTEX.
Sign up for free →Open GPCR on ORTEX